CSPC Pharmaceutical Group Ltd 2021 AR2
The report outlines the financial and operational performance of CSPC Pharmaceutical Group Limited for the fiscal year 2021. The company achieved a revenue growth of 11.7% to RMB 27,867 million, driven by its finished drugs and bulk products businesses. CSPC continued to advance its research and development, with R&D expenses increasing by 18.8% to RMB 3,433 million and over 50 key drug candidates entering clinical trials. Additionally, the company's MSCI ESG rating was upgraded from BBB to A in 2021, reflecting its commitment to sustainable development.
Company: CSPC Pharmaceutical Group Ltd
Sector: Health Care
Country: China
Year: 2021
Type: AR2
Pages: 177
Back to company
CSPC Pharmaceutical Group Ltd
Annual Report
The report outlines the financial and operational performance of CSPC Pharmaceutical Group Limited for the fiscal year 2021. The company achieved a revenue growth of 11.7% to RMB 27,867 million, driven by its finished drugs and bulk products businesses. CSPC continued to advance its research and development, with R&D expenses increasing by 18.8% to RMB 3,433 million and over 50 key drug candidates entering clinical trials. Additionally, the company's MSCI ESG rating was upgraded from BBB to A in 2021, reflecting its commitment to sustainable development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees